Capillary regeneration in scleroderma: Stem cell therapy reverses phenotype?

PLoS ONE

Volumn 3, Issue 1, 2008, Pages

  Fleming, Jo N ^a   Nash, Richard A ^b   McLeod, D O ^a   Florentino, David F ^c   Shulman, Howard M ^b   Connolly, M Kari ^d   Molitor, Jerry A ^e   Henstorf, Gretchen ^b   Lafyatis, Robert ^f   Pritchard, David K ^a   Adams, Lawrence D ^a   Furst, Daniel E ^g   Schwartz, Stephen M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CADHERIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; RGS PROTEIN; RGS5 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROANGIOPATHY; MORPHOGENESIS; MORPHOMETRICS; PHENOTYPE; PROTEIN EXPRESSION; SCAR FORMATION; SCLERODERMA; SKIN BIOPSY; SKIN CAPILLARY; TISSUE REGENERATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; CAPILLARY; DIFFUSE SCLERODERMA; PHYSIOLOGY; REGENERATION; STEM CELL TRANSPLANTATION;

CAPILLARIES; HUMANS; PHENOTYPE; REGENERATION; SCLERODERMA, DIFFUSE; STEM CELL TRANSPLANTATION;

EID: 39049171830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001452     Document Type: Article

References (76)

1. Jimenez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 22: 647-674.
2. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675-694.
3. Sapadin AN, Esser AC, Fleischmajer R (2001) Immunopathogenesis of scleroderma- evolving concepts. Mt Sinai J Med 68: 233-242.
4. Handa R, Kumar U, Pandey RM, Aggarwal P, Biswas A, Wali JP (2002) Raynaud's Phenomenon-A Prospective Study. J Ind Acad Clin Med 3: 35-38.
5. Kahaleh MB (2004) Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 22: S19-S23.
6. Jones NF (2003) Surgical Treatment of the Hand in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 269-277.
7. Carpentier PH, Maricq HR (1990) Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 16: 75-91.
8. Larcher F, Murillas R, Bolontrade M, Conti C, Jorcano JL (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene Volume 17: 303-311.
9. Isner JM (2000) Tissue responses to ischemia: local and remote responses for preserving perfusion of ischemic muscle. J Clin Invest Volume 106: 615-619.
10. Detmar M, Brown L, Schön M, Elicker B, Velasco P, et al. (1998) Increased Microvacular density and enhanced leukocyte rolling in the skin of VEGF transgeinic mice. J Invest Dermatol 111: 1-6.
11. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, et al. (2003) Elevated vascular endothefial growth factor in systemic sclerosis. J Rheumatol 30: 1529-1533.
12. Shore AC (2000) Capillaroscopy and assestment of capillary pressure. British Journal of Clinical Pharmacology Volume 50: 501-513.
13. Houben AJ, Beljaars JH, Hofstra L, Kroon AA, De, Leeuw PW (2003) Microvascular abnormalities in chronic heart failure: a cross-sectional analysis. Microcirculation 10: 471-478.
14. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA (1999) Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 34: 655-658.
15. Denton CP, Black CM (2003) Pulmonary Vascular Involvement in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 184-193.
16. White B (2003) Pulmonary Fibrosis in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 163-183.
17. Herrick AL (2003) Nervous System Involvement in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 309-318.
18. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, et al, (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100: 1602-1610.
19. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C, et al. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study. Blood 110: 1388-1396.
20. Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, et al. (2006) Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 54: 1982-1986.
21. Garlanda C, Dejana E (1997) Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vase Biol 17: 1193-1202.
22. Newman PJ, Hillery CA, Albrecht R, Parise LV, Berndt MC, et al. (1992) Activation-dependent changes in human platelet PECAM-1: Phosphorylation, cytoskeletal association, and surface membrane redistribution. J Cell Biol 119: 239-246.
23. Higgins JC, Eady RA (1981) Human dermal microvasculature: II. Enzyme histochemical and cytochemical study. Br J Dermatol 104: 521-529.
24. Duijvestijn AM, Horst E, Pals ST, Rouse BN, Steere AC, et al. (1988) High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. Am J Pathol 130: 147-155.
25. Girard JP, Springer TA (1995) High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 16: 449-457.
26. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, et al. (1991) Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 138: 791-798.
27. Romero LI, Zhang DN, Herron GS, Karasek MA (1977) Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol 173: 84-92.
28. Gruschwitz M, von den DP, Kellner I, Hornstein OP, Sterry W (1992) Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 27: 169-177.
29. Nystedt S, Ramakrishnan V, Sundelin J (1996) The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 271: 14910-14915.
30. Steinberg SF (2005) The cardiovascular actions of protease-activated receptors. Mol Pharmacol 67: 2-11.
31. Cederqvist K, Haglund C, Heikkila P, Hollenberg MD, Karikoski R, et al. (2005) High expression of pulmonary proteinase-activated receptor 2 in acute and chronic lung injury in preterm infants. Pediatr Res 57: 831-836.
32. Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, et al. (1999) Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 8: 282-294.
33. Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, et al. (2000) Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol 278: L193-L201.
34. D'Andrea MR, Rogahn CJ, Andrade-Gordon P (2000) Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech Histochem 75: 85-90.
35. Rivera-Nieves J, Burcin TL, Olson TS, Morris MA, McDuffie M, et al. (2006) Critical role of endothelial P-selectin glycoprotein figand 1 in chronic murine ileitis. J Exp Med 203: 907-917.
36. Sperandio M, Smith ML, Forlow SB, Olson TS, Xia L, et al. (2003) P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J Exp Med 197: 1355-1363.
37. Facchetti F, Vermi W, Mason D, Colonna M (2003) The plasmacytoid monocyte/interferon producing cells. Virchows Arch 443: 703-717.
38. Goodbourn S, Didcock L, Randall R (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 81: 2341-2364.
39. Wieland T, Mittmann C (2003) Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol Ther 97: 95-115.
40. Adams LD, Geary RL, McManus B, Schwartz SM (2000) A comparison of aorta and vena cava medial message expression by cDNA array analysis identifies a set of 68 consistently differentially expressed genes, all in aortic media. Circ Res 87: 623-631.
41. Cho H, Kozasa T, Bondjers C, Betsholtz C, Kehil JH (2003) Pericyte-specific expression of RGS5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J 17: 440-442.
42. Gown AM, Willingham MC (2002) Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 50: 449-454.
43. Medsger Jr TA (2003) Classification, Purpose. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 17-28.
44. Clements PJ, Medsger Jr TA, Feghali CA (2003) Cutaneous Involvement in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 129-130.
45. Antonios TF, Rattray FM, Singer DR, Markandu ND, Mortimer PS, et al. (2003) Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 89: 175-178.
46. Braverman IM (2000) The cutaneous microcirculation. J Investig Dermatol Symp Proc 5: 3-9.
47. Wallez Y, Vilgrain I, Huber P (2006) Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55-59.
48. Distler O, Distler JH, Scheid A, Acker T, Hirth A, et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95: 109-116.
49. Liu X, Zhu S, Wang T, Hummers L, Wigley FM, et al. (2005) Baclitaxel Modulates TGFB Signaling in Scleroderma Skin Grafts in Immumodeficient Mice. PLoS Med 2: e354.
50. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, et al. (1995) Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 92: 4562-4566.
51. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, et al. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11: 1368-1375.
52. Bielenberg D, McCarty MF, Bucana CD, Yuspa. SH, Morgan D, et al. (1999) Expression of Interferon- is Associated with Growth Arrest of Murine and Human Epidermal Cells. Journal of Investigative Dermatology 112: 802-809.
53. Beretta L, Caronni M, Vanoli M, Scorza R (2002) Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol 147: 385-386.
54. Bachmeyer C, Farge D, Gluckman E, Miclea JM, Aractingi S (1996) Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol 135: 481-483.
55. Black CM, Silman AJ, Herrick AI, Denton CP, et al. (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42: 299-305.
56. Theofilopoulos AN, Baccala R, Beutler B, Kono D (2004) TYPE I INTERFERONS (a/B) IN IMMUNITY AND AUTOIMMUNITY. Annual Review of Immunology 23: 307-335.
57. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, et al. (2002) Plasmacytoid dendritic cells: a new cutaneous dendritic, cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119: 1096-1102.
58. York MJR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.
59. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, et al. (1999) The nature of the principal type I interferon-producing cells in human blood. Science 284: 1835-1837.
60. Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140: 37-50.
61. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364: 603-610.
62. Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 20: 1325-1330.
63. Renaudineau Y, Grunebaum E, Krause I, Praprotnik S, Revelen R, et al. (2001) Anti-endothelial cell antibodies (AECA) in systemic sclerosis-increased sensitivity using different endothetial cell substrates and association with other autoanti-bodies. Autoimmunity 33: 171-179.
64. Trotta F, Biagini G, Cenacchi G, Ballardini G, Varotti C, et al. (1984) Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 2: 209-215.
65. Clough G, Church M (2005) Vascular Responses in Human Skin. In: Shepro D, D'Amore PA, Black C, Garcia JG, Granger DN, et al. (?005) Microvascular Research; Biology and Pathology. London: Elsevier Academic Press. pp 565-572.
66. Gerritsen M (2005) Endothelial Heterogeneity. In: Shepro D, et al. (2005) MICROVASCULAR RESEARCH: BIOLOGY AND PATHOLOGY. London: Elsevier. pp 51-56.
67. Senger DR, Van-de WL, Brown LF, Nagy JA, Yeo KT, et al. (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324.
68. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
69. Asahara T, Isner JM (2002) Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11: 171-178.
70. Murayama T, Asahara T (2002) Bone marrow-derived endothelial progenitor cells for vascular regeneration. Curr Opin Mol Ther 4: 395-402.
71. Isner JM, Kalka C, Kawamoto A, Asahara T (2001) Bone marrow is a source of endothelial cells for natural and iatrogenic, vascular repair. Ann N Y Acad Sci 953: 75-84.
72. Storck J, Zhao Z, Lin E, Berger T, McSweency PA, et al. (2001) Recovery from and consequences of severe iatrogenic lymphopenia. (induced to treat autoimmune diseases). Clinical Immunology 113: 285-298.
73. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, et al. (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201: 805-816.
74. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, et al. (2006) Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107: 1696-1702.
75. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, et al. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182: 155-162.
76. Komminoth P (1996) Detection of mRNA in tissue sections using DIG-labeled RNA and oligonucleotide probes. In: Grunewald-Jahno S, ed (1996) Non-Radioactive in Situ Hybridization Application Manual. Mannheim: Boehringer. pp 126-135.